Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system
This investigation offered novel prospects for monitoring and addressing undesirable medication effects associated with amivantamab, which might improve the clinical medication safety.
Authors
- Panwei Hu (ORCID: https://orcid.org/0000-0002-2101-0481)
- Dongqiang Zeng (ORCID: https://orcid.org/0000-0001-9724-8325)
- Yufan Yang (ORCID: https://orcid.org/0000-0003-0737-8367)
- Luyang Jiang
- Wenjun Qiu
- Jiani Wu
- Qianqian Mao (ORCID: https://orcid.org/0000-0003-3332-2922)
- Min Li (ORCID: https://orcid.org/0000-0002-4965-4617)
- Jian Wu (ORCID: https://orcid.org/0000-0002-3394-1507)
- Yiran Fang
- Wangjun Liao
- Xiatong Huang
- Xiang Fu (ORCID: https://orcid.org/0009-0003-1691-6283)
Institutions
- Shanghai University of Traditional Chinese Medicine (CN)
- Shuguang Hospital (CN)
- Southern Medical University (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1080/14740338.2025.2471512
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation